Targeting specific gene fusions that drive aggressive sarcomas
Official title: Leveraging Retained Partner Gene Function to Effectively Target CIC-rearranged Fusion Oncoproteins
Funded at University of California, San Francisco · NIH-10995787 · Data updated 2026-11-12
This study is looking at how specific gene changes, especially involving the CIC gene, might lead to aggressive sarcomas, with the goal of finding better treatments for patients facing this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $45,909 |
| NIH project number | 1F31CA287493-01A1 |
| Project ID | NIH-10995787 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with aggressive sarcomas that involve CIC gene fusions.
✕Less likely to help
Patients with sarcomas not associated with CIC gene fusions may not benefit from this research.
What this research studies
This research investigates how certain gene fusions, particularly involving the Capicua (CIC) gene, contribute to the development of aggressive sarcomas. By understanding the biological mechanisms behind these fusions, the project aims to identify more effective treatment strategies. The researchers will utilize advanced techniques, including dynamic microscopy and patient-derived cell lines, to study the behavior of these fusion proteins in a laboratory setting. This approach seeks to uncover how these proteins function and how they can be targeted for therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive sarcomas caused by CIC gene fusions.
How similar studies have gone: While research on CIC gene fusions is limited, similar approaches targeting specific oncogenic fusions have shown promise in other cancer types.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Luck, Cuyler — University of California, San Francisco
- Study coordinator: Luck, Cuyler
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.